Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

333
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
333
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

923
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
923

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.

Blood immunology & cellular therapy·2026
Same author

Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma.

Blood·2026
Same author

Clinical decision support in hematological malignancies using a case-grounded AI agent.

Nature medicine·2026
Same author

Expanded antigen-specific donor regulatory T cells for GVHD prevention.

Blood·2026
Same author

Correction: Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

JAMA oncology·2026

相关实验视频

Updated: Jul 9, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

识别,定义和管理CAR-T血液毒性.

Kai Rejeski1,2, Marion Subklewe1,2, Frederick L Locke3

  • 1Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Hematology. American Society of Hematology. Education Program
|December 9, 2023
PubMed
概括

卡尔-T疗法可能导致显著的血液毒性,称为免疫效应细胞相关的血液毒性 (ICAHT). 管理策略,包括生长因子和干细胞增强,对于患者的康复至关重要.

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 血液学 血液学 血液学

更多相关视频

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

933
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K

相关实验视频

Last Updated: Jul 9, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

933
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K

背景情况:

  • 自主CAR-T细胞疗法 (CAR-T) 为B细胞恶性瘤提供了改善的结果,但具有已知的毒性,如CRS和ICANS.
  • 除了规范性毒性之外,CAR-T与显著的血液学不良事件有关,需要谨慎管理.

结论:

  • 有效管理与CAR-T相关的血液毒性对于患者安全和治疗成功至关重要.
  • 标准化诊断标准和风险分层工具,如CAR-HEMATOTOX,对于风险适应管理至关重要.
  • 需要进一步的研究和临床警,以优化对接受CAR-T治疗的患者的护理.